[Skip to Content]
[Skip to Content Landing]
May 17, 1985

Controlled Trials for Neonatal Meningitis-Reply

Author Affiliations

University of Texas Health Science Center at Dallas

JAMA. 1985;253(19):2833. doi:10.1001/jama.1985.03350430042017

In Reply.—  There are many factors that influence the predisposition to and outcome from bacterial meningitis in newborns. The prospective, randomized controlled designs of the three Neonatal Meningitis Cooperative Studies attempted to distribute risk factors among the therapeutic groups in order to compare an untested therapeutic regimen with conventional therapy. Given the vicissitudes of coordinating many centers throughout the world in the projects, we were generally successful in having comparable population characteristics in the different treatment groups. Although not mentioned in our article describing the results of the Third Neonatal Meningitis Cooperative Study, there were no differences in the rates or types of obstetrical complications in infants who received ampicillin and moxalactam compared with those receiving ampicillin and amikacin sulfate.Because infants enrolled from centers in Latin America were older and had a different distribution of etiologic agents than did those from the United States and Europe, we analyzed and